Zobrazeno 1 - 10 of 54 pro vyhledávání: '"Jonathan A Tobert"'
1
Targeting PCSK9 with Antibodies and Gene Silencing to Reduce LDL-cholesterol
Autor: Connie B Newman, Jonathan A Tobert
Publikováno v: The Journal of clinical endocrinology and metabolism.
The discovery of PCSK9 and its role in regulating the low-density lipoprotein (LDL) receptor, and the effect of loss-of-function mutations of its gene, identified it as a therapeutic target in 2006. Fully humanized monoclonal antibodies to PCSK9 (ali
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174985029f83c8f1c9a474852c192636
https://pubmed.ncbi.nlm.nih.gov/36469793
Zobrazit plný text záznamu
2
LDL Cholesterol-How Low Can We Go?
Autor: Jonathan A. Tobert
Publikováno v: Endocrinology and metabolism clinics of North America. 51(3)
Combinations of lipid-lowering agents can often bring LDL cholesterol down to around 40 mg/dL (1 mmol/L). Randomized controlled trials indicate that this reduces the risk of atherosclerotic vascular events with minimal adverse effects. This has raise
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::059cd44bd01e8f4b16d07c00fce990e8
https://pubmed.ncbi.nlm.nih.gov/35963635
Zobrazit plný text záznamu
3
Lipid-modifying agents, from statins to PCSK9 inhibitors
Autor: Christina Reith, David Preiss, Jonathan A. Tobert, G. Kees Hovingh
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower LDL-cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL-cholesterol lowering treatment. Data from
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f79994c89ff378d258e78348e19ea84
https://doi.org/10.1016/j.jacc.2019.11.072
Zobrazit plný text záznamu
6
Statin tolerability: In defence of placebo-controlled trials
Autor: Jonathan A. Tobert, Connie B. Newman
Publikováno v: European Journal of Preventive Cardiology
Background Statin intolerance is a barrier to effective lipid-lowering treatment. A significant number of patients stop prescribed statins, or can take only a reduced dose, because of adverse events attributed to the statin, and are then considered s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a41af75a5e1808dd478281288db0dad
https://doi.org/10.1177/2047487315602861
Zobrazit plný text záznamu
7
Now is good, earlier is better
Autor: Jonathan A. Tobert, David Preiss
Publikováno v: European Heart Journal. Quality of Care & Clinical Outcomes. 3(4)
There is abundant evidence that lowering LDL cholesterol with statins reduces cardiovascular risk both in those without symptomatic atherosclerotic disease (primary prevention), and those who have already suffered an atherosclerotic complication, suc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ae163a7d42138639b79c88d918c117
http://ora.ox.ac.uk/objects/uuid:
Zobrazit plný text záznamu
9
The nocebo effect in the context of statin intolerance
Autor: Connie B. Newman, Jonathan A. Tobert
Publikováno v: Journal of clinical lipidology. 10(4)
The nocebo effect, the inverse of the placebo effect, is a well-established phenomenon that is under-appreciated in cardiovascular medicine. It refers to adverse events, usually purely subjective, that result from expectations of harm from a drug, pl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edab6b3d533589c708c98bb6770090ed
https://pubmed.ncbi.nlm.nih.gov/27578103
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje